Skip to content

ACCESS to the Cardiac Cath Lab in Patients Without STEMI Resuscitated From Out-of-hospital VT/VF Cardiac Arrest

ACCESS to the Cardiac Catheterization Laboratory in Patients Without ST-segment Elevation Myocardial Infarction Resuscitated From Out-of-hospital Ventricular Fibrillation Cardiac Arrest

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03119571
Enrollment
65
Registered
2017-04-18
Start date
2017-12-12
Completion date
2019-11-26
Last updated
2021-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest Due to Underlying Cardiac Condition, Cardiopulmonary Arrest With Successful Resuscitation, Ventricular Fibrillation

Keywords

Cardiac arrest, Ventricular fibrillation, coronary artery disease

Brief summary

To determine if survival to hospital discharge with good neurological outcome for adults ages 18-75 who are resuscitated from out-of-hospital VT/VF cardiac arrest without clinical signs of a heart attack do better by going straight to the cardiac catheterization laboratory or admitted to the intensive care unit for evaluation. The investigators think a large portion of resuscitated patients presenting with VT/VF have ischemic heart disease which is the cause for the arrest. And prompt access to the cardiac catheterization laboratory to reverse the blocked artery will improve survival with good neurological outcomes.

Detailed description

Primary Aim Determine survival to hospital discharge with Modified Rankin Scale Score (mRS) ≤ 3 in adult (18-75 years old) patients resuscitated from out-of-hospital VT/VF cardiac arrest who do not have ST-segment elevation on emergency department 12-lead ECG (no-STEMI) randomized to receive either: 1) initial CCL admission, or 2) initial ICU admission. Hypothesis: The corresponding hypothesis is that a large proportion of all resuscitated patients presenting with VT/VF have ischemic heart disease as the underlying cause for the participants cardiac arrest and that a strategy to facilitate prompt revascularization in all patients presenting with VT/VF who do not have ST-segment elevation on emergency department 12-lead ECG will improve survival with good neurological outcome. Primary Endpoint Survival to hospital discharge with mRS ≤ 3 Secondary Aims Determine secondary assessments of survival, left ventricular function, hospital duration, and rehabilitation in-hospital and assessment of survival and functional status at 3 months in both groups. Hypothesis: The corresponding hypothesis is that initial CCL admission will result in improved secondary assessment values at 3 months. Secondary Endpoints In-hospital secondary endpoints: Survival to hospital discharge, CPC score, mean peak troponin level, mean ejection fraction, mean length of ICU stay, mean hospitalization duration, the incidence of and mean length of rehabilitation. 3-month post-hospital discharge secondary endpoint: Survival to 3 months, survival to 3 months with mRS ≤ 3, functional status at 3 months (CPC score), incidence and length of rehabilitation, incidence of congestive heart failure, incidence of re-hospitalization over 3 months, and incidence and time to return to work. Pragmatic Clinical Trial The ACCESS Trial will randomize patients to receive one of two standard treatments currently practiced in the United States: either, 1) initial CCL admission, or 2) initial ICU admission. Other than randomizing to one of these two standard treatments, care is not otherwise specified and is completely at the discretion of the treating clinician, including coronary interventions, if any, hemodynamic support, medications, therapeutic hypothermia, and all other interventions and clinical care.

Interventions

PROCEDUREInitial CCL admission

Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions

DIAGNOSTIC_TESTInitial ICU admission

Evaluate for additional testing and/or procedures

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Adult presumed or known to be 18-75 years old * Resuscitated from OOHCA * Initial cardiac arrest rhythm of pulseless VT/VF (including patients treated with an AED) * No ST-segment elevation MI (No STEMI) (or STEMI-equivalent syndrome) on ED 12-lead ECG (as interpreted by a physician)

Exclusion criteria

* Initial non-shockable out-of-hospital cardiac arrest rhythm (pulseless electrical activity or asystole) * Valid do not resuscitate orders (DNR), * Blunt, penetrating, or burn-related injury, drowning, electrocution or known overdose, * Known prisoners * Known pregnancy, * ST-segment elevation on ED 12-lead ECG (as interpreted by a physician) * Absolute contraindications to emergent coronary angiography including, * known anaphylactic reaction to angiographic contrast media, * active gastrointestinal or internal bleeding, or * severe concomitant illness that drastically shortens life expectancy or increases risk of the procedure. * Suspected or confirmed intracranial bleeding * Refractory cardiac arrest (prior to randomization) * Patients meeting ACCESS Trial eligibility criteria initially seen in an outside hospital and then transferred to an ACCESS Trial participating hospital

Design outcomes

Primary

MeasureTime frameDescription
Survival to Hospital Discharge With mRS ≤ 3Up to 3 weeksOutcome is reported as the percent of participants who survive to hospital discharge with an mRS score less than or equal to 3. The Modified Rankin Score (mRS) is a 6-point scale measuring disability. Scores range from 0 (no disability) to 5 (severe disability; bedridden, incontinent, requires continuous care). Higher scores indicate greater disability. A sixth category is often added for patients who expire.

Countries

Canada, United States

Participant flow

Participants by arm

ArmCount
Initial CCL Admission
Admission to the CCL to evaluate the coronary artery disease Initial CCL admission: Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions
31
Initial ICU Admission
Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team. Initial ICU admission: Evaluate for additional testing and/or procedures
34
Total65

Baseline characteristics

CharacteristicInitial CCL AdmissionInitial ICU AdmissionTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
9 Participants12 Participants21 Participants
Age, Categorical
Between 18 and 65 years
22 Participants22 Participants44 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants24 Participants48 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
6 Participants9 Participants15 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
4 Participants1 Participants5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
6 Participants4 Participants10 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
20 Participants29 Participants49 Participants
Region of Enrollment
Canada
0 participants1 participants1 participants
Region of Enrollment
United States
31 participants33 participants64 participants
Sex: Female, Male
Female
8 Participants13 Participants21 Participants
Sex: Female, Male
Male
23 Participants21 Participants44 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
7 / 317 / 34
other
Total, other adverse events
0 / 310 / 34
serious
Total, serious adverse events
12 / 3118 / 34

Outcome results

Primary

Survival to Hospital Discharge With mRS ≤ 3

Outcome is reported as the percent of participants who survive to hospital discharge with an mRS score less than or equal to 3. The Modified Rankin Score (mRS) is a 6-point scale measuring disability. Scores range from 0 (no disability) to 5 (severe disability; bedridden, incontinent, requires continuous care). Higher scores indicate greater disability. A sixth category is often added for patients who expire.

Time frame: Up to 3 weeks

Population: Of the 34 participants in the ICU group, 27 survived to discharge and 7 died. Of the 31 participants in the CCL group, 24 survived to discharge, and 7 died.

ArmMeasureValue (NUMBER)
Initial CCL AdmissionSurvival to Hospital Discharge With mRS ≤ 367.7 percentage of participants
Initial ICU AdmissionSurvival to Hospital Discharge With mRS ≤ 373.5 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026